FDA's Regulatory Flexibility Tested Under Interim Leadership

The U.S. Food and Drug Administration (FDA) is currently in a transitional period following the departure of Commissioner Marty Makary and changes in the administration. The new drug approvals scheduled for this quarter will serve as a benchmark for the agency's regulatory flexibility under its interim leadership. Wall Street analysts are closely watching to see if the FDA will establish a more business-friendly approach to drug approvals, which could significantly impact overall R&D investment sentiment.

Capricor and Takeda Targeting Unmet Needs in Rare Diseases and Neurological Disorders

Capricor Therapeutics (CAPR)'s DMD cardiomyopathy cell therapy, 'deramiocel,' is scheduled for a final approval review on August 22. After the FDA declined to approve the drug in July of last year, the company has resubmitted the application with additional Phase 3 data. The outcome of this review is of great interest to the industry. Meanwhile, Takeda Pharmaceutical (TAK) is awaiting the outcome of its priority review for 'oveporexton,' an orexin receptor agonist targeting the narcolepsy market, which is estimated to be worth $2 billion to $3 billion. The decision is expected in the third quarter.

Moderna's mRNA Flu Vaccine Approval and Platform Diversification Strategy

Moderna (MRNA)'s mRNA-based flu vaccine, 'mRNA-1010,' has a PDUFA target date of August 5, putting it to the test as part of the company's platform diversification strategy. This vaccine is crucial for Moderna, which has been struggling with declining sales of its COVID-19 vaccine, as it will expand the company's commercial portfolio. The vaccine received a unanimous positive recommendation from the FDA's Advisory Committee (VRBPAC) in June, raising expectations for its approval. The approval would allow the mRNA vaccine to overcome existing production limitations and respond quickly to variants.

Celcuity's 'Gedatolisib' Challenging the Breast Cancer Treatment Paradigm

Celcuity (CELC)'s breast cancer treatment, 'gedatolisib,' is a pan-PI3K/mTOR inhibitor and is scheduled for an FDA decision on July 17. 'Gedatolisib' targets hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer patients and is positioned as an alternative to existing treatments with high side effects. The review is based on data from a Phase 3 trial (VIKTORIA-1) and will determine whether the drug can enter the market as a strong competitor to existing drugs such as Novartis' 'Piqray.'

Merck's 'Enlicitide' to Revolutionize the Oral PCSK9 Inhibitor Market

Merck (MRK)'s hypercholesterolemia treatment, 'enlicitide,' is the first once-daily oral PCSK9 inhibitor, with a target approval date in the second half of 2026. Compared to existing injectable drugs such as Amgen's 'Repatha' and Regeneron's 'Praluent,' 'enlicitide' offers greater convenience and has the potential to significantly change prescribing patterns in primary care settings. Merck is using a priority review voucher to expedite the review process and considers the drug to be a key asset to offset the expected decline in sales of 'Keytruda' after its patent expires.